A Pfizer spokesperson confirmed the news today, saying: "On March 7, 2022, the New York Stock Exchange (NYSE) filed a Form 25 (Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934) related to the delisting of Pfizer’s 0.250% Notes due 2022.
"The 0.250% Notes due 2022 were euro-denominated notes that were paid in full on March 7, 2022 in accordance with their terms and maturity date. As a result, the 0.250% Notes due 2022 are no longer outstanding and thus are delisted from the NYSE. Pfizer’s Common Stock, $.05 par value (“PFE”) and Pfizer’s 1.000% Notes due 2027 (“PFE27”) continue to be listed on the New York Stock Exchange."
The Pfizer spokesperson provided no further commentary.
Court-mandated Pfizer documents unsealed
The news comes on the back of a stormy week in which court-mandated documents are being released by the FDA pertaining to its review of the clinical trials in support of Pfizer/BioNTech's Covid-19 vaccine license.
The court order will see 55,000 pages of Pfizer data released per month that was used to authorise their Covid-19 vaccine produced with BioNTech. BioNTech is a German biotechnology company based in Mainz with a branch in Cape Town, South Africa (https://www.radbiontech.com/)?? - that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
Both Pfizer (an American company) and BioNTech (a German company) were producing the Pfizer-BioNTech Cominarty Covid-19 vaccine. The documents under contention show 1291 listed adverse events linked to the Pfizer-BioNTech vaccine.
It is unclear whether the de-listed Pfizer will be acquired by BioNTech, and if so what formula will be used to fill the Covid-19 vaccines distributed by BioNTech going forward, and whether BioNTech will be supplying South Africans with Covid-19 vaccines.
ANYTHING CAN HAPPEN TO YOUR INVESTMENTS PLEASE DO YOUR DD BEFORE INVESTING AND MAKE $$$$$$$